Drugs / HSV-Tk
HSV-Tk
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03338777 | Feb 2020 | melanoma | Hospital Italiano de Buenos Aires | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03603405 | Feb 2018 → Dec 2026 expected | anaplastic astrocytoma, glioblastoma | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03596086 | Dec 2017 → Dec 2026 expected | anaplastic astrocytoma, glioblastoma | David Baskin MD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00423124 | Jul 2002 → Dec 2011 | hematopoietic and lymphoid cell neoplasm | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03541928 | Aug 2018 → Jul 2023 | prostate cancer | The Methodist Hospital Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03004183 | Jul 2017 → Jul 2022 | non-small cell lung carcinoma, triple-negative breast carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02831933 | Feb 2017 → Nov 2020 | non-small cell squamous lung carcinoma, uveal melanoma | Eric Bernicker, MD | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00914628 | Apr 2010 → Nov 2019 | acute leukemia | AGC Biologics S.p.A. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSVt k | “the suicide gene system (HSV thymidine kinase: HSVt k)” NCT03338777 ↗ |
| Known as | ADV/HSV-tk | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03603405 ↗ |
| Known as | HSV thymidine kinase | “the suicide gene system (HSV thymidine kinase: HSVt k)” NCT03338777 ↗ |
| Known as | TK-cells | “In a phase I-II, multicentre, non-randomised trial of haploidentical stem-cell transplantation, we infused donor lymphocytes expressing herpes-simplex thymidine kinase suicide...” PMID 19345145 ↗ Apr 2009 |
| Modality | Cell therapy | “Infusion of genetically modified lymphocytes” NCT00423124 ↗ |
| Route | Other | “will be injected intratumorally on day 0 of the study” NCT02831933 ↗ |